Embryonic stem cell-derived motoneurons provide a highly sensitive cell culture model for botulinum neurotoxin studies, with implications for high-throughput drug discovery

Stem Cell Research

Volumn 6, Issue 3, 2011, Pages 195-205

  Kiris, Erkan ^a,b   Nuss, Jonathan E ^a   Burnett, James C ^b,c   Kota, Krishna P ^a   Koh, Dawn C ^b   Wanner, Laura M ^a   Torres Melendez, Edna ^a   Gussio, Rick ^b   Tessarollo, Lino ^b   Bavari, Sina ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL ISOLATION; CHOLINERGIC TRANSMISSION; CONTROLLED STUDY; DRUG OVERDOSE; DRUG RESEARCH; EMBRYONIC STEM CELL; ENVIRONMENTAL EXPOSURE; ESTHETICS; EXOCYTOSIS; HIGH THROUGHPUT SCREENING; IMMUNOFLUORESCENCE; MOTONEURON; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPRODUCIBILITY; SPINAL CORD MOTONEURON; SYNAPTIC TRANSMISSION;

ANIMALS; BOTULINUM ANTITOXIN; BOTULINUM TOXINS; CELL DIFFERENTIATION; CELLS, CULTURED; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; EMBRYONIC STEM CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; MOTOR NEURONS; SYNAPTOSOMAL-ASSOCIATED PROTEIN 25;

MAMMALIA;

EID: 79955023053     PISSN: 18735061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.scr.2011.01.002     Document Type: Article

References (59)

1. Adler M., Keller J.E., Sheridan R.E., Deshpande S.S. Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle. Toxicon 2001, 39:233-243.
2. American Society for Aesthetic Plastic Surgery Cosmetic Surgery National Data Bank Statistics Available at, Accessed November 02, 2010. http://www.surgery.org/sites/default/files/2008stats.pdf.
3. Antonucci F., Rossi C., Gianfranceschi L., Rossetto O., Caleo M. Long-distance retrograde effects of botulinum neurotoxin A. J. Neurosci. 2008, 28:3689-3696.
4. Apland J.P., Biser J.A., Adler M., Ferrer-Montiel A.V., Montal M., Canaves J.M., Filbert M.G. Peptides that mimic the carboxy-terminal domain of SNAP-25 block acetylcholine release at an Aplysia synapse. J. Appl. Toxicol. 1999, 19(Suppl. 1):S23-S26.
5. Apland J.P., Adler M., Oyler G.A. Inhibition of neurotransmitter release by peptides that mimic the N-terminal domain of SNAP-25. J. Protein Chem. 2003, 22:147-153.
6. Arnon S.S., Schechter R., Inglesby T.V., Henderson D.A., Bartlett J.G., Ascher M.S., Eitzen E., Fine A.D., Hauer J., Layton M., Lillibridge S., Osterholm M.T., O'Toole T., Parker G., Perl T.M., Russell P.K., Swerdlow D.L., Tonat K. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001, 285:1059-1070.
7. Bajohrs M., Rickman C., Binz T., Davletov B. A molecular basis underlying differences in the toxicity of botulinum serotypes A and E. EMBO Rep. 2004, 5:1090-1095.
8. Bakry N., Kamata Y., Simpson L.L. Lectins from Triticum vulgaris and Limax flavus are universal antagonists of botulinum neurotoxin and tetanus toxin. J. Pharmacol. Exp. Ther. 1991, 258:830-836.
9. Baldwin M.R., Barbieri J.T. Association of botulinum neurotoxins with synaptic vesicle protein complexes. Toxicon 2009, 54:570-574.
10. Blasi J., Chapman E.R., Link E., Binz T., Yamasaki S., De Camilli P., Sudhof T.C., Niemann H., Jahn R. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 1993, 365:160-163.
11. Brin M.F. Development of future indications for BOTOX. Toxicon 2009, 54:668-674.
12. Burnett J.C., Henchal E.A., Schmaljohn A.L., Bavari S. The evolving field of biodefence: therapeutic developments and diagnostics. Nat. Rev. 2005, 4:281-297.
13. Caleo M., Antonucci F., Restani L., Mazzocchio R. A reappraisal of the central effects of botulinum neurotoxin type A: by what mechanism?. J. Neurochem. 2009, 109:15-24.
14. Camu W., Henderson C.E. Purification of embryonic rat motoneurons by panning on a monoclonal antibody to the low-affinity NGF receptor. J. Neurosci. Methods 1992, 44:59-70.
15. Cashman N.R., Durham H.D., Blusztajn J.K., Oda K., Tabira T., Shaw I.T., Dahrouge S., Antel J.P. Neuroblastoma x spinal cord (NSC) hybrid cell lines resemble developing motor neurons. Dev. Dyn. 1992, 194:209-221.
16. Centers for Disease Control and Prevention Specific Bioterrorism Agents Available at, Accessed November 02, 2010. http://www.bt.cdc.gov/agent/agentlist-category.asp.
17. Chen S., Barbieri J.T. Engineering botulinum neurotoxin to extend therapeutic intervention. Proc. Natl Acad. Sci. USA 2009, 106:9180-9184.
18. Coffield J.A., Yan X. Neuritogenic actions of botulinum neurotoxin a on cultured motor neurons. J. Pharmacol. Exp. Ther. 2009, 330:352-358.
19. Dolly J.O., Lawrence G.W., Meng J., Wang J., Ovsepian S.V. Neuro-exocytosis: botulinum toxins as inhibitory probes and versatile therapeutics. Curr. Opin. Pharmacol. 2009, 9:326-335.
20. Domeniconi M., Hempstead B.L., Chao M.V. Pro-NGF secreted by astrocytes promotes motor neuron cell death. Mol. Cell. Neurosci. 2007, 34:271-279.
21. Dong M., Tepp W.H., Johnson E.A., Chapman E.R. Using fluorescent sensors to detect botulinum neurotoxin activity in vitro and in living cells. Proc. Natl Acad. Sci. USA 2004, 101:14701-14706.
22. Dong M., Yeh F., Tepp W.H., Dean C., Johnson E.A., Janz R., Chapman E.R. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006, 312:592-596.
23. Fagan R.P., McLaughlin J.B., Middaugh J.P. Persistence of botulinum toxin in patients' serum: Alaska, 1959-2007. J. Infect. Dis. 2009, 199:1029-1031.
24. Foster K.A., Adams E.J., Durose L., Cruttwell C.J., Marks E., Shone C.C., Chaddock J.A., Cox C.L., Heaton C., Sutton J.M., Wayne J., Alexander F.C., Rogers D.F. Re-engineering the target specificity of Clostridial neurotoxins-a route to novel therapeutics. Neurotox. Res. 2006, 9:101-107.
25. Grumelli C., Verderio C., Pozzi D., Rossetto O., Montecucco C., Matteoli M. Internalization and mechanism of action of clostridial toxins in neurons. Neurotoxicology 2005, 26:761-767.
26. Hakami R.M., Ruthel G., Stahl A.M., Bavari S. Gaining ground: assays for therapeutics against botulinum neurotoxin. Trends Microbiol. 2010, 18:164-172.
27. Harper J.M., Krishnan C., Darman J.S., Deshpande D.M., Peck S., Shats I., Backovic S., Rothstein J.D., Kerr D.A. Axonal growth of embryonic stem cell-derived motoneurons in vitro and in motoneuron-injured adult rats. Proc. Natl Acad. Sci. USA 2004, 101:7123-7128.
28. Infant Botulism Treatment and Prevention Program Division of Communicable Disease Control, California Department of Public Health. What is BabyBIG? Available at, Accessed November 02, 2010. http://www.infantbotulism.org/.
29. Jankovic J. Botulinum toxin in clinical practice. J. Neurol. Neurosurg. Psychiatry 2004, 75:951-957.
30. Kalandakanond S., Coffield J.A. Cleavage of SNAP-25 by botulinum toxin type A requires receptor-mediated endocytosis, pH-dependent translocation, and zinc. J. Pharmacol. Exp. Ther. 2001, 296:980-986.
31. Keller J.E., Neale E.A. The role of the synaptic protein snap-25 in the potency of botulinum neurotoxin type A. J. Biol. Chem. 2001, 276:13476-13482.
32. Keller J.E., Neale E.A., Oyler G., Adler M. Persistence of botulinum neurotoxin action in cultured spinal cord cells. FEBS Lett. 1999, 456:137-142.
33. Keller J.E., Cai F., Neale E.A. Uptake of botulinum neurotoxin into cultured neurons. Biochemistry 2004, 43:526-532.
34. Lamanna C. The most poisonous poison. Science 1959, 130:763-772.
35. Larsen J.C. U.S. Army botulinum neurotoxin (BoNT) medical therapeutics research program: past accomplishments and future directions. Drug Dev. Res. 2009,266-278.
36. Li X.J., Hu B.Y., Jones S.A., Zhang Y.S., Lavaute T., Du Z.W., Zhang S.C. Directed differentiation of ventral spinal progenitors and motor neurons from human embryonic stem cells by small molecules. Stem Cells 2008, 26:886-893.
37. Mahrhold S., Rummel A., Bigalke H., Davletov B., Binz T. The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett. 2006, 580:2011-2014.
38. Miles G.B., Yohn D.C., Wichterle H., Jessell T.M., Rafuse V.F., Brownstone R.M. Functional properties of motoneurons derived from mouse embryonic stem cells. J. Neurosci. 2004, 24:7848-7858.
39. Montecucco C., Molgo J. Botulinal neurotoxins: revival of an old killer. Curr. Opin. Pharmacol. 2005, 5:274-279.
40. Moscatelli I., Pierantozzi E., Camaioni A., Siracusa G., Campagnolo L. p75 neurotrophin receptor is involved in proliferation of undifferentiated mouse embryonic stem cells. Exp. Cell Res. 2009, 315:3220-3232.
41. Neale E.A., Bowers L.M., Jia M., Bateman K.E., Williamson L.C. Botulinum neurotoxin A blocks synaptic vesicle exocytosis but not endocytosis at the nerve terminal. J. Cell Biol. 1999, 147:1249-1260.
42. Nuss J.E., Ruthel G., Tressler L.E., Wanner L.M., Torres-Melendez E., Hale M.L., Bavari S. Development of cell-based assays to measure botulinum neurotoxin serotype A activity using cleavage-sensitive antibodies. J. Biomol. Screen. 2010, 15:42-51.
43. Panchal R.G., Kota K.P., Spurgers K.B., Ruthel G., Tran J.P., Boltz R.C., Bavari S. Development of high-content imaging assays for lethal viral pathogens. J. Biomol. Screen. 2010, 15:755-765.
44. Pellett S., Tepp W.H., Clancy C.M., Borodic G.E., Johnson E.A. A neuronal cell-based botulinum neurotoxin assay for highly sensitive and specific detection of neutralizing serum antibodies. FEBS Lett. 2007, 581:4803-4808.
45. Pitts E.V., Potluri S., Hess D.M., Balice-Gordon R.J. Neurotrophin and Trk-mediated signaling in the neuromuscular system. Int. Anesthesiol. Clin. 2006, 44:21-76.
46. Rossetto O., Schiavo G., Montecucco C., Poulain B., Deloye F., Lozzi L., Shone C.C. SNARE motif and neurotoxins. Nature 1994, 372:415-416.
47. Rossetto O., Morbiato L., Caccin P., Rigoni M., Montecucco C. Presynaptic enzymatic neurotoxins. J. Neurochem. 2006, 97:1534-1545.
48. Savino P.J., Maus M. Botulinum toxin therapy. Neurol. Clin. 1991, 9:205-224.
49. Sheridan R.E., Smith T.J., Adler M. Primary cell culture for evaluation of botulinum neurotoxin antagonists. Toxicon 2005, 45:377-382.
50. Simpson L.L. Identification of the major steps in botulinum toxin action. Annu. Rev. Pharmacol. Toxicol. 2004, 44:167-193.
51. Simpson L.L., Coffield J.A., Bakry N. Inhibition of vacuolar adenosine triphosphatase antagonizes the effects of clostridial neurotoxins but not phospholipase A2 neurotoxins. J. Pharmacol. Exp. Ther. 1994, 269:256-262.
52. Soundararajan P., Miles G.B., Rubin L.L., Brownstone R.M., Rafuse V.F. Motoneurons derived from embryonic stem cells express transcription factors and develop phenotypes characteristic of medial motor column neurons. J. Neurosci. 2006, 26:3256-3268.
53. Stahl A.M., Ruthel G., Torres-Melendez E., Kenny T.A., Panchal R.G., Bavari S. Primary cultures of embryonic chicken neurons for sensitive cell-based assay of botulinum neurotoxin: implications for therapeutic discovery. J. Biomol. Screen. 2007, 12:370-377.
54. Wang J., Meng J., Lawrence G.W., Zurawski T.H., Sasse A., Bodeker M.O., Gilmore M.A., Fernandez-Salas E., Francis J., Steward L.E., Aoki K.R., Dolly J.O. Novel chimeras of botulinum neurotoxins A and E unveil contributions from the binding, translocation, and protease domains to their functional characteristics. J. Biol. Chem. 2008, 283:16993-17002.
55. Wein L.M., Liu Y. Analyzing a bioterror attack on the food supply: the case of botulinum toxin in milk. Proc. Natl Acad. Sci. USA 2005, 102:9984-9989.
56. Wichterle H., Peljto M. Differentiation of mouse embryonic stem cells to spinal motor neurons. Curr. Protoc. Stem Cell Biol. 2008, 5. Unit 1H.1.1-1H.1.9.
57. Wichterle H., Lieberam I., Porter J.A., Jessell T.M. Directed differentiation of embryonic stem cells into motor neurons. Cell 2002, 110:385-397.
58. Wichterle H., Peljto M., Nedelec S. Xenotransplantation of embryonic stem cell-derived motor neurons into the developing chick spinal cord. Methods Mol. Biol. 2009, 482:171-183.
59. Wiese S., Herrmann T., Drepper C., Jablonka S., Funk N., Klausmeyer A., Rogers M.L., Rush R., Sendtner M. Isolation and enrichment of embryonic mouse motoneurons from the lumbar spinal cord of individual mouse embryos. Nat. Protoc. 2009, 5:31-38.